Gilead Sciences, Inc. GILD reported better-than-expected third-quarter results and raised its annual earnings guidance.

For patients who are unable to tolerate or who refuse surgery, endoscopic biliary sphincterotomy or treatment with ursodeoxycholic acid are reasonable alternatives. Additional controlled ...

Investors' focus is likely to be on GILD???s HIV franchise performance and oncology sales when the company reports ...

For primary biliary cirrhosis, ursodeoxycholic acid is safe and is the first choice for treatment. Treatment of this autoimmune liver disease should also address various symptoms and complications ...

The US agency has cleared seladelpar under the Livdelzi brand name as a second-line therapy for PBC in adults, either in combination with ursodeoxycholic acid (UDCA) or as monotherapy for those ...

who do not respond or are intolerant to standard first-line therapy with ursodeoxycholic acid (UDCA), with a decision due by 14th August. Out of 99 patients from seladelpar studies who have been ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2024 results of operations. “Gilead’s third quarter results are the strongest o ...